Wells Fargo raises TRAX price target to $62, keeps Overweight

Wells Fargo increased its price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and maintained an Overweight rating. The firm said Teva (TEVA) and Argenx (ARGX) showing efficacy in celiac disease supports its confidence in ANB033, and it sees upcoming Q4 2026 and Q1 2027 datasets as opportunities for differentiation.